Clinical Trials Browser

OTHER × Triple Negative Breast Neoplasms × Liposomes × Clear all

NCT01333423 2012-06-26

Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)

Phase 1 Withdrawn

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms